Therefore, the potential combination of inhibiting both Ref-1/APE1 redox function and STAT3/survivin provides an avenue of targeting both the overarching regulator and downstream effector of an anti-apoptotic pathway integral to prostate cancer. Here, APEX1 is linked to prostate carcinoma.